AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.   (Currently Amended)   A powdered pharmaceutical composition for treating asthma bronchiale in mammals, comprising: [[,]]

separately or together,

an efficacious amount of (i) loteprednol or loteprednol etabonate; and (ii) at least one β_2 adrenoreceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,

for simultaneous, sequential, or separate administration by inhalation in the treatment of asthma bronchiale in mammals, wherein the pharmaceutical composition is formulated in a powdered form.

2.   (Currently Amended)   The powdered pharmaceutical composition according to claim 1, comprising:

(i) loteprednol or loteprednol etabonate; and

(ii) formoterol.

3.   (Currently Amended)   The powdered pharmaceutical composition according to claim 1, comprising:

(i) loteprednol or loteprednol etabonate; and

(ii) salmeterol.

4.   (Currently Amended)   The powdered pharmaceutical composition according to claim 1, comprising:

(i) loteprednol or loteprednol etabonate; and

(ii) reproterol.

5.   (Canceled).

6.   (Canceled).

7.   (Currently Amended)   A method for the treatment of asthma bronchiale in a patient, the method comprising:

administering to a the patient in need of such treatment an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,

if appropriate together with

wherein a pharmaceutically acceptable excipient or a vehicle is added if suitable excipients or vehicles, for simultaneous, sequential or separate administration.

8.   (Currently Amended)   A process for the preparation of a pharmaceutical composition for the treatment of asthma bronchiale, the process comprising:

combining (i) an effective amount of the active compound loteprednol or loteprednol etabonate and (ii) an effective amount of at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,

wherein the loteprednol or loteprednol etabonate and the β_2 adrenoceptor agonist or the one or more β_2 adrenoceptor agonists are mixed individually or together,

if appropriate together with

wherein a pharmaceutically acceptable excipient or a vehicle is added if suitable, excipients or vehicles, and

wherein the mixture composition thus obtained is converted into suitable a powdered administration forms form suitable for inhalations.